Global anti-asthma drugs market Information, by type of asthma (allergic (extrinsic) and non-allergic (intrinsic) asthma), by asthma trigger type (child-onset asthma, adult-onset asthma, exercise-induced asthma, cough-induced asthma, occupational asthma, nocturnal asthma, steroid-resistant asthma (severe asthma)), by drug class (bronchodilators (beta agonists, anti-cholinergics, xanthines), leukotriene antagonists, mast cell stabilizers, corticosteroids, monoclonal antibody), by therapy (reliever treatment and maintenance treatment) and by route of administration (oral, inhaled, intravenous, subcutaneous)- Forecast to 2022

Pune, India -- (SBWire) -- 08/07/2017 --Market Highlights

Anti-asthma drugs are used for the treatment of asthma which is a disease of the airways resulting in narrowing and inflammation of air tubes, accompanied by increased secretion, swelling and build-up of tissue fluid characterized by symptoms such as tight chest, wheezing, cough and may be limitation of activity due to difficulty in breathing. As of 2015, almost 300 million people suffer from the disease and the numbers are rising which has been blamed primarily on rising pollution especially particulates.

The present market of anti-asthma drugs is valued at USD 18.9 billion in 2015 and is projected to grow to USD 28.3 billion in 2022 representing a CAGR of 5.94 %.

The developed region anti-asthma drug market is flat and the key will be to tap the huge potential of developing region market. Thus market diversification will be of prime importance for growth. Another strategy will be development of novel biological anti-asthma drugs which is a drug class of future. Development of curative anti-asthma drug will be the single most important development and will make the first comer the leader till the patent expires. The uptake of any novel drug will be extremely fast with low marketing cost due to lack of any curative anti-asthma drug.

Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/2353

The market however is fragmented with a number of players and there is good penetration of generics. The loss of patents of some blockbusters such as Advair and Symbicort has numbed the market but these constraints are not enough to hold on for long. Thus taking all these factors together we expect a moderate growth potential of CAGR of 5.94%.

Major Key Players

- GlaxoSmithKline plc.,
- Merck & Co., Inc.,
- AstraZeneca plc.,
- F. Hoffmann-La Roche Ltd,
- Teva Pharmaceutical Industries,
- Novartis International AG,
- Boehringer Ingelheim,
- Sunovion Pharmaceuticals Inc.

Regional Analysis:

Depending on geographic region, Anti-asthma drug market is segmented into four key regions: Americas, Europe, Asia Pacific, and Middle East & Africa. Globally developed countries led by North America is the largest market for Anti-asthma drugs. Europe is the second-largest market for anti-asthma drugs. The developing regions market such as Asia pacific region and Middle East & Africa however is rising much faster and will dominate in the near future.

Test the market data and market information presented through more than 60 market data tables and figures spread over 80 numbers of pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on "Global Anti-asthma Drug Market Research Report - Forecast to 2022".

Access Report Details @ https://www.marketresearchfuture.com/reports/anti-asthma-drugs-market-2353

Segmentation:

Global anti-asthma drugs market has been segmented on the basis of type (allergic (extrinsic) and non-allergic (intrinsic)), by trigger (child-onset, adult-onset, exercise-induced, cough-induced, occupational, nocturnal, steroid-resistant), by therapy (reliever treatment and maintenance treatment), by drug class (Bronchodilators (beta agonists, anti-cholinergics, xanthines), leukotriene antagonists, mast cell stabilizers, corticosteroids, monoclonal antibody) and by route of administration (oral, inhaled, intravenous, subcutaneous).

Table of Content

6 Global anti-asthma drugs market, by trigger
6.1 Introduction
6.1.1 Child-onset asthma
6.1.2 Adult-onset asthma
6.1.3 Exercise-induced asthma
6.1.4 Cough-induced asthma
6.1.5 Occupational asthma
6.1.6 Nocturnal asthma
6.1.7 Steroid-resistant asthma
7 Global anti-asthma drugs market, by drug class
7.1 Introduction
7.1.1 Bronchodilators (beta agonists, anti-cholinergics, xanthines)
7.1.2 Leukotriene antagonists
7.1.3 Mast cell stabilizers
7.1.4 Corticosteroids
7.1.5 Monoclonal antibody
7.1.6 Others
8 Global anti-asthma drugs market, by therapy
8.1 Introduction
8.1.1 Preventive
8.1.2 Curative
Continued….

Browse Related Statistical Report

North America Lung Cancer Market, is projected to grow at a CAGR of 8.8 % and is expected to reach US$ 3,196.2 million by 2023. In North America Lung Cancer Market, US accounted for the largest market share in 2016.

https://www.marketresearchfuture.com/statistical-reports/north-america-lung-cancer-market-3662

About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact:
Akash Anand,
Market Research Future
+1 646 845 9312
Email: akash.anand@marketresearchfuture.com